mRNA 치료제 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of mRNA therapeutics Market

The global mRNA therapeutics market is undergoing a period of rapid evolution, driven by unprecedented scientific advancements, expanding biotechnology capabilities, and successful commercialization of mRNA-based vaccines during the COVID-19 pandemic. According to the latest market intelligence, the global mRNA therapeutics market size reached USD 8.91 billion in 2024, supported by robust R&D activities and rising acceptance of mRNA vaccines. However, the market is projected to decrease to USD 6.01 billion in 2025 due to normalization in COVID-19 vaccine demand and shifts in immunization programs worldwide. Despite this temporary contraction, the market is expected to surge to USD 21.45 billion by 2032, driven by innovation, expanding therapeutic applications, and accelerating pipeline development, achieving a CAGR of 19.9% between 2025 and 2032.

The mRNA field has fundamentally reshaped the pharmaceutical landscape. What was once considered an experimental platform has rapidly emerged as a transformational technology capable of addressing infectious diseases, cancer, rare genetic disorders, and personalized medicine. The successful deployment of mRNA COVID-19 vaccines-Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna)-validated the potential of mRNA-based therapeutics and established strong global market confidence.

North America dominated the global market with a 35.12% share in 2024, valued at USD 3.13 billion, owing to its world-leading research infrastructure, substantial public and private funding, and strong presence of major pharmaceutical innovators such as Moderna, Pfizer, BioNTech, and GSK.

The decline in 2025 reflects reduced COVID-19 vaccination campaigns. However, post-2026, the market is anticipated to return to strong double-digit expansion as diverse pipelines move closer to commercialization.

Drivers Shaping Market Growth

1. Advantages of mRNA Therapeutics

mRNA therapies offer several unique advantages over small molecules, DNA vaccines, and conventional biologics:

• Rapid development timeline
• Strong immune response
• Safety advantages (no integration into host genome)
• High potency with small dosages
• Easy adaptability to new strains

These benefits are accelerating the development of mRNA vaccines for infectious diseases like influenza, RSV, Mpox, Zika, malaria, and HIV, as well as therapeutic vaccines for cancer and protein-replacement therapies.

2. Expanding Applications Beyond Vaccines

Though vaccines dominate current market revenues, mRNA therapies are expanding into:

• Oncology (e.g., personalized cancer vaccines)
• Genetic diseases (e.g., enzyme replacement therapies)
• Protein therapy
• Cardiovascular disease
• Autoimmune disorders

The drugs/medications segment is expected to become the fastest-growing category post-2027, supported by the anticipated launch of the first mRNA drug in 2027 and projections that the mRNA drug market will reach USD 2 billion by 2032 at a CAGR of 118.7% from 2027 to 2032.

Market Restraints

1. Storage and Stability Challenges

mRNA molecules require ultra-cold temperatures for stability. This continues to hinder adoption in regions with limited cold-chain infrastructure, particularly low-income countries.

2. High Manufacturing Costs

mRNA production involves:

• Multiple purification steps
• Specialized facilities
• Complex lipid nanoparticle (LNP) formulation
• Stringent regulatory compliance

These factors contribute to high capital expenditures and limited global production capacity.

3. Regulatory and Public Acceptance Issues

The regulatory framework for mRNA drugs is still evolving. Despite strong scientific backing, skepticism persists among certain segments of the population, particularly regarding new vaccine technologies.

Key Market Trends

Growing Adoption of mRNA in Drug Development

There has been substantial growth in clinical trials globally, with approximately 40% of mRNA-based clinical trials in Phase I as of 2022. Companies are using mRNA for:

• Personalized oncology vaccines
• Intratumoral injections
• Immunotherapies

Multiple partnerships, acquisitions, and collaborations indicate a strong pipeline across the industry.

Breakthrough Innovations in Delivery Technologies

LNPs, polymers, and cationic nanoparticles are improving:

• mRNA stability
• Targeted delivery
• Cellular uptake

These innovations reduce toxicity and allow broader therapeutic applications.

Segmentation Analysis

By Type

Prophylactic (Vaccines) - Dominant in 2024

The vaccines segment accounted for the highest share in 2024 due to COVID-19 and RSV vaccine approvals.

Approved products include:

• Comirnaty (Pfizer/BioNTech)
• Spikevax (Moderna)
• mRESVIA (Moderna - RSV vaccine)

Non-COVID vaccines in the pipeline include:

• Seasonal influenza (mRNA-1010)
• Mpox
• Malaria
• Cytomegalovirus (CMV)

Drugs/Medications - Fastest Growing Segment

Expected boom after 2027 as mRNA therapeutics enter commercialization, especially in oncology.

By Application

Infectious Diseases - Leading in 2024

Because all approved mRNA products as of early 2025 target infectious diseases, this segment dominates.

Oncology - High Future Growth

Multiple cancer vaccines are in development, including BioNTech's BNT116 for NSCLC.

By Distribution Channel

• Hospital Pharmacies dominated in 2024 due to vaccination programs.
• Retail Pharmacies expected to grow with broader product approvals.

Regional Outlook

North America - Market Leader (2024 Value: USD 3.13 Billion)

Key drivers:

• Significant government funding (e.g., USD 590 million to Moderna in 2025)
• Strong biotech startup ecosystem
• Rapid regulatory approvals
• High awareness and adoption

Europe

Germany and France lead the region with major companies such as BioNTech, CureVac, and Sanofi.

Asia Pacific

Fastest-growing region, driven by:

• China's approval of its first homegrown mRNA COVID-19 vaccine in 2023
• High investment in oncology trials
• Partnerships for manufacturing and development

Rest of the World

Latin America and Middle East & Africa show rising interest as healthcare infrastructure improves.

Competitive Landscape

Major players include:

• Moderna Inc.
• BioNTech SE
• Pfizer Inc.
• CureVac SE
• GSK plc.
• Sanofi
• Omega Therapeutics
• Strand Therapeutics

These companies are investing heavily in:

• Clinical pipeline expansion
• Delivery technology innovation
• Large-scale biomanufacturing facilities
• Cross-border partnerships

Conclusion

The global mRNA therapeutics market is transforming rapidly, driven by technological innovation, expanded pipeline applications, rising funding, and growing acceptance of mRNA-based medicines. While the market dips from USD 8.91 billion in 2024 to USD 6.01 billion in 2025, it is set to rebound strongly, reaching USD 21.45 billion by 2032. With breakthroughs expected across oncology, infectious diseases, and rare genetic disorders, mRNA technology is positioned to become one of the most influential healthcare innovations of the 21st century.

Segmentation

By Type

• Prophylactic (Vaccines)
  • COVID-19 Vaccines
  • Non-COVID-19 Vaccines
• Drugs/Medications

By Application

• Oncology
• Infectious Diseases
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Others

By Region

• North America (By Type, Application, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Type, Application, Distribution Channel, and Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific (By Type, Application, Distribution Channel, and Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of the Asia Pacific
• Rest of the World (By Type, Application, Distribution Channel)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview: Advancements in mRNA Technology
• 4.2. Future Growth Prospects for mRNA Therapeutics
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
• 4.5. Impact of Tariff on the Market

5. Global mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Prophylactic (Vaccines)
    • 5.1.1.1. COVID-19 Vaccines
    • 5.1.1.2. Non-COVID-19 Vaccines
  • 5.1.2. Drugs/Medications
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Oncology
  • 5.2.2. Infectious Diseases
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Drug Stores & Retail Pharmacies
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Prophylactic (Vaccines)
    • 6.1.1.1. COVID-19 Vaccines
    • 6.1.1.2. Non-COVID-19 Vaccines
  • 6.1.2. Drugs/Medications
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Oncology
  • 6.2.2. Infectious Diseases
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Drug Stores & Retail Pharmacies
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Prophylactic (Vaccines)
    • 7.1.1.1. COVID-19 Vaccines
    • 7.1.1.2. Non-COVID-19 Vaccines
  • 7.1.2. Drugs/Medications
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Oncology
  • 7.2.2. Infectious Diseases
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Drug Stores & Retail Pharmacies
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Rest of Europe

8. Asia Pacific mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Prophylactic (Vaccines)
    • 8.1.1.1. COVID-19 Vaccines
    • 8.1.1.2. Non-COVID-19 Vaccines
  • 8.1.2. Drugs/Medications
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Oncology
  • 8.2.2. Infectious Diseases
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Drug Stores & Retail Pharmacies
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Rest of the World mRNA Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Prophylactic (Vaccines)
    • 9.1.1.1. COVID-19 Vaccines
    • 9.1.1.2. Non-COVID-19 Vaccines
  • 9.1.2. Drugs/Medications
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Oncology
  • 9.2.2. Infectious Diseases
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Drug Stores & Retail Pharmacies
  • 9.3.3. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2024)
• 10.2. Company Profiles
  • 10.2.1. Moderna Inc.
    • 10.2.1.1. Overview
    • 10.2.1.2. Products & services
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. BioNTech
    • 10.2.2.1. Overview
    • 10.2.2.2. Products & services
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Pfizer Inc.
    • 10.2.3.1. Overview
    • 10.2.3.2. Products & services
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. CureVac SE
    • 10.2.4.1. Overview
    • 10.2.4.2. Products & services
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. GSK plc
    • 10.2.5.1. Overview
    • 10.2.5.2. Products & services
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. Sanofi
    • 10.2.6.1. Overview
    • 10.2.6.2. Products & services
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. Omega Therapeutics
    • 10.2.7.1. Overview
    • 10.2.7.2. Products & services
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. Strand Therapeutics
    • 10.2.8.1. Overview
    • 10.2.8.2. Products & services
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)
  • 10.2.9. Immunomic Therapeutics
    • 10.2.9.1. Overview
    • 10.2.9.2. Products & services
    • 10.2.9.3. SWOT Analysis
    • 10.2.9.4. Recent Developments
    • 10.2.9.5. Strategies
    • 10.2.9.6. Financials (Based on Availability)